European Medicines Agency workshop on pharmacogenomics: from science to clinical care

  • Email
  • Help

Details

TitleEuropean Medicines Agency workshop on pharmacogenomics: from science to clinical care
Date08/10/2012 - 09/10/2012
LocationEuropean Medicines Agency, London, UK
SummaryThis workshop's topics include current methodological, regulatory and public health implication of pharmacogenomics from drug discovery, medicines evaluation to clinical use. Its objectives are to share international expert views, discuss challenges and identify areas for joint stakeholder action. Registration closed.

All documents

Name Language First published Last updated
Agenda - Workshop on pharmacogenomics: from science to clinical care (English only) 19/09/2012  
European Medicines Agency workshop on pharmacogenomics: from science to clinical care - Invitation for expressions of interest (English only) 30/04/2012 10/05/2012
Report - European Medicines Agency workshop on pharmacogenomics (English only) 21/11/2012  
Presentation - Genomics in science and clinical care (English only) 21/11/2012  
Presentation - Pharmacogenomics in rare diseases: Development strategy for ivacaftor as a therapy for cystic fibrosis (English only) 21/11/2012  
Presentation - Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products (English only) 21/11/2012  
Presentation - Clinical pharmacogenomics: Premarketing evaluation in early-phase clinical studies (English only) 21/11/2012  
Presentation - Methodological issues (some) relating to patient selection - CHMP reflection paper (English only) 21/11/2012  
Presentation - Adaptive designs for the development of targeted therapies (English only) 21/11/2012  
Presentation - Evaluation and implementation challenges with genomic signatures in clinical drug development (English only) 21/11/2012  
Presentation - Opportunities for public health and pharmacogenomics from the new pharmacovigilance legislation (English only) 21/11/2012  
Presentation - Concept paper on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products (English only) 21/11/2012  
Presentation - Session 3: Post-approval pharmacogenomics: impact on risk management (English only) 21/11/2012  
Presentation - Pharmacogenomics: a long(er) learning curve? (English only) 21/11/2012  
Presentation - Session 4 : Pharmacogenomics-guided treatments in clinical care: experience from patients and healthcare professionals (English only) 21/11/2012  
Presentation - Pharmacogenetic clinical implementation: a seven-year experience (English only) 21/11/2012  
Presentation - Revision of the European Union Directive on in-vitro diagnostic medical devices (English only) 21/11/2012  
Presentation - Regulation, innovation and personalised medicine (English only) 21/11/2012  
Presentation - Health-technology assessment of companion diagnostics (English only) 21/11/2012  
Presentation - Genomics in patients with Hispanic ancestry (English only) 21/11/2012  
Presentation - Genomics in patients with Japanese ancestry (English only) 21/11/2012  
Presentation - Differences in a biomarker’s predictive ability across racial groups (English only) 21/11/2012  

Media Videos